Outlook on the Biologics Contract Manufacturing Global Market to 2031 – Focus on Monoclonal Antibodies, Recombinant Proteins, Vaccines and Molecular Therapy – ResearchAndMarkets.com

Outlook on the Biologics Contract Manufacturing Global Market to 2031 – Focus on Monoclonal Antibodies, Recombinant Proteins, Vaccines and Molecular Therapy – ResearchAndMarkets.com




Outlook on the Biologics Contract Manufacturing Global Market to 2031 – Focus on Monoclonal Antibodies, Recombinant Proteins, Vaccines and Molecular Therapy – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Biologics Contract Manufacturing Market – Asia Pacific Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering.

The latest study analyzes the historical and present scenario of the biologics contract manufacturing market in Asia Pacific to gauge its growth potential.

The study presents detailed information about important growth factors, restraints, and key trends that are creating the landscape for growth of the biologics contract manufacturing market in Asia Pacific in order to identify opportunities for stakeholders. The report also provides insightful information about the growth of the biologics contract manufacturing market in Asia Pacific during the forecast period from 2021 to 2031.

The report offers intricate dynamics about different aspects of the biologics contract manufacturing market in Asia Pacific, which aids companies operating in the market in making strategic decisions. This study also elaborates on the significant changes that are anticipated to boost the growth of the biologics contract manufacturing market in Asia Pacific during the forecast period. It also includes key indicator assessment that highlights growth prospects of the biologics contract manufacturing market in Asia Pacific and provides statistics related to the market in terms of value (US$ Mn).

This study covers detailed segmentation of the biologics contract manufacturing market in Asia Pacific, along with key information and competition outlook. The report provides company profiles of players that dominate the biologics contract manufacturing market in Asia Pacific, wherein various developments, expansions, and winning strategies adopted by these players have been presented in detail.

Companies Mentioned

  • Lonza Group
  • Samsung Biologics Co., Ltd.
  • Patheon by Thermo Fisher Scientific, Inc.
  • Cambrex Corporation
  • Siegfried Holding AG
  • Fujifilm Holding Corporation
  • AbbVie, Inc.
  • Boehringer Ingelheim
  • Recipharm Pharmaceuticals
  • WuXi Biologics
  • Catalent, Inc.

Key Questions Answered in this Report on Asia Pacific Biologics Contract Manufacturing Market

The report provides detailed information about the biologics contract manufacturing market in Asia Pacific based on comprehensive research on various factors that play a key role in accelerating the growth of the market. Information mentioned in the report answers path-breaking questions for companies that currently operate in the biologics contract manufacturing market in Asia Pacific and are looking for innovative methods to create a unique benchmark in the market in order to help them design successful strategies and make target-driven decisions.

  • Which segment of the biologics contract manufacturing market in Asia Pacific would emerge as a major revenue generator during the forecast period?
  • How are key market players successfully earning revenue in the biologics contract manufacturing market in Asia Pacific?
  • What would be the Y-o-Y growth trend of the biologics contract manufacturing market in Asia Pacific between 2021 and 2031?
  • What are the winning imperatives of leading players operating in the biologics contract manufacturing market in Asia Pacific?

Key Topics Covered:

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global & Asia Pacific Biologics Contract Manufacturing Market

4. Market Overview

4.1. Introduction

4.1.1. Segment Definition

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global & Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, 2017-2031

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Biologics Contract Manufacturing: Overview

5.2. Trends in Biopharma Contract Manufacturing

5.3. Key Industry Events (mergers, acquisitions, collaborations, approvals, etc.)

5.4. COVID-19 Pandemic Impact on Industry

6. Global & Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, by Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast, by Type, 2017-2031

6.3.1. Monoclonal Antibodies

6.3.2. Recombinant Proteins

6.3.3. Vaccines

6.3.4. Molecular Therapy

6.3.5. Others

6.4. Market Attractiveness Analysis, by Type

7. Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast, by Country/Sub-Region

8. Japan Biologics Contract Manufacturing Market Analysis and Forecast

9. South Korea Biologics Contract Manufacturing Market Analysis and Forecast

10. Taiwan Biologics Contract Manufacturing Market Analysis and Forecast

11. Singapore Biologics Contract Manufacturing Market Analysis and Forecast

12. Thailand Biologics Contract Manufacturing Market Analysis and Forecast

13. India Biologics Contract Manufacturing Market Analysis and Forecast

14. Rest of Asia Pacific Biologics Contract Manufacturing Market Analysis and Forecast

15. Competition Landscape

For more information about this report visit https://www.researchandmarkets.com/r/eav9bw

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900